Articles tagged with Chemotherapy
Dr Yeo's study found that prophylactic lamivudine significantly reduces the incidence of HBV reactivation and hepatitis in breast cancer patients. The drug was effective in reducing the risk of liver damage caused by HBV reactivation during and after chemotherapy.
Researchers found that high S-phase fraction and diploid status were key predictors of early and late recurrence rates. Patients with poor prognostic indicators, including older age at diagnosis and larger tumor size, had poorer outcomes.
A new clinical trial called TREE-2 is evaluating the safety and efficacy of three regimens of ELoxatin as a first-line treatment for patients with metastatic colorectal cancer. The study combines an effective anti-angiogenesis antibody with chemotherapy to improve treatment outcomes.
According to Dr. McDougall, high-fat low-carbohydrate diets can increase the risk of heart disease, kidney failure, colon cancer, and more. In contrast, populations that consume high-carbohydrate foods tend to have a lower risk of these conditions.
The future of drug delivery involves 'smart' systems addressing issues like gut, skin, and lung penetration, promising improved patient compliance and treatment efficacy.
Women experience a range of physical symptoms, including hot flashes and vaginal dryness, following breast cancer treatment. Mood and emotional functioning are similar among all women at the end of primary treatment.
A widely used anti-nausea drug, dexamethasone, may interfere with cancer chemotherapy. Pretreatment with dexamethasone reduces the ability of paclitaxel and doxorubicin to kill cancer cells by upregulating genes that protect breast cancer cells from cell death.
Phenoxodiol, a chemo-sensitizer, has shown encouraging results in treating late-stage ovarian cancer. The study found 25% response rates and synergy with chemotherapy, suggesting potential benefits for patients.
Researchers found that a combination of surgery and intraperitoneal hyperthermic chemotherapy (IPHC) can increase survival rates for patients with peritoneal carcinomatosis. The procedure, which delivers heated chemotherapy directly to the tumor site, has shown promise in improving quality of life and extending survival.
A study from Duke University Medical Center found that virtual reality interventions significantly reduced symptom distress and fatigue in breast cancer patients during chemotherapy. Participants reported a decrease in nausea and vomiting, as well as improved mental state, after using the technology.
A meta-analysis of genetic counseling for breast, ovarian, and colorectal cancer found improved knowledge of cancer genetics, but no impact on perceived risk. A gene mutation affecting folate metabolism alters the sensitivity of colon and breast cancer cells to chemotherapy drugs.
A new study suggests that premenopausal women with ER-negative breast cancer may benefit from adjuvant chemotherapy alone or followed by goserelin, while those with ER-positive tumors show no significant difference in outcomes. The findings support the idea of ovarian suppression as a treatment alternative for some premenopausal women.
A nationwide survey found that 56% of women with early stage breast cancer received less than 85% of their prescribed chemotherapy dose intensity. Treatment delays and dose reductions were common due to neutropenia, a shortage of infection-fighting white blood cells.
St. Jude scientists have discovered a new method to target the Topoisomerase 1 enzyme, crucial for cell division, leading to potential novel anti-cancer drugs that can work in combination with existing agents. This approach may also reduce cancer cells' ability to become resistant to treatment.
Researchers at the University of Texas M. D. Anderson Cancer Center found that pairing Gleevec with high-dose chemotherapy produces a synergistic effect in patients with Philadelphia-positive ALL, resulting in complete remissions that have lasted up to 29 months. The two-year disease-free survival rate is 85 percent, offering a promisi...
A phase II trial found that AMD-3100, a new drug, increases the availability of stem cells in cancer patients undergoing transplantation. This boosts the chances of successful transplantation and may reduce the number of collections needed.
A recent study found that over 20% of patients with estrogen-negative breast cancer had a complete pathologic response to treatment, compared to just 5% in estrogen-positive cancers. The researchers suggest that endocrine therapies may be a more effective initial treatment for these patients.
A study of 362 patients has shown that breast conservation after neoadjuvant chemotherapy is a safe and effective alternative to mastectomy for many patients. The key to success lies in careful patient selection and coordination among treatment specialists, with low rates of local-regional recurrence reported.
A new study found that chemotherapy and radiation together is more effective than sequential treatment in preserving the voice box, with 88% of patients still having their voice after two years. Overall survival rates were similar for all three treatment options.
Researchers at Fox Chase Cancer Center discovered a novel DNA-repair gene mutation that causes resistance to cancer drugs, particularly in colorectal cancer. The defective MED1 enzyme interferes with chemotherapy's effectiveness, making cancers resistant to widely used treatments.
Researchers found decreased tumor blood flow correlated significantly with survival in patients treated with neoadjuvant chemotherapy. The study suggests tumor biology should be an important factor in considering patient response to treatment.
Researchers used transarterial chemoembolization (TACE) to treat patients with liver tumors, shrinking them by up to 35% in size. Patients who responded successfully were then treated with laser-induced thermotherapy (LITT), allowing for a more aggressive approach to tumor treatment while preserving patient quality of life.
Women with BRCA1 mutations have a poorer prognosis for breast cancer compared to those without the mutation. However, chemotherapy may improve survival rates for these patients. The study suggests that physicians should consider BRCA1 mutation status when making treatment decisions.
Researchers at Johns Hopkins Kimmel Cancer Center have discovered a gene silencer that blocks cancer cells' ability to repair themselves after chemotherapy and radiation. By reducing the production of targeted repair proteins, the silencer enables cancer cells to become susceptible to therapy.
A new study found that adding aprepitant to standard treatment for nausea and vomiting can effectively prevent these symptoms following chemotherapy. The medication reduced nausea and vomiting both on the day of chemotherapy administration and in the days that followed.
A study found that using aggressive chemotherapy with high doses of methotrexate, asparaginase, and doxorubicin improves survival rates for children with T-cell acute lymphoblastic leukemia by 15 percentage points. The new approach also showed minimal long-term effects beyond those seen in lower-dose treatment regimens.
A new study found that adjuvant chemotherapy did not improve survival rates for patients with surgically removed non-small-cell lung cancer. Additionally, a study on selenium supplementation revealed that it may increase the risk of squamous cell carcinoma and total nonmelanoma skin cancer in individuals at high risk.
A large-scale clinical study by Nordic collaboration has provided new insights into the effects of chemotherapy in colorectal cancer. The analysis demonstrated that among 2,223 patients, those given chemotherapy as part of routine care had a five-year survival rate of 56%, compared to 49% for those treated by surgery alone.
A multi-center study found improved overall survival and time to disease progression for women with metastatic breast cancer treated with Taxotere, compared to paclitaxel. The results suggest that Taxotere may be a more effective treatment option for this patient population.
A Phase III trial found that docetaxel significantly improved survival rates and overall response rates compared to paclitaxel in women with advanced, incurable breast cancer. The median survival time was 15.4 months for docetaxel patients versus 12.7 months for paclitaxel patients.
A meta-analysis of 14 trials showed no survival benefit with chemotherapy, but adjuvant radiotherapy resulted in a 7% higher mortality rate. Professor Thatcher suggests further research is needed to confirm the result.
A Phase III study shows that Avastin, an anti-angiogenic agent, extends patient survival time to 20.3 months when added to first-line chemotherapy. The treatment also improves response rates and duration of response across all relevant patient subgroups.
Two new studies found that elderly lung cancer patients benefit equally from aggressive chemotherapy and radiation treatment, contradicting common assumptions. Fit elderly patients should be fully briefed on treatment options, including potential risks and benefits. The studies suggest presenting the full range of treatment options to ...
A new study reveals that patients who received neoadjuvant chemotherapy lived an average of 31 months longer than those treated with surgery alone. The combination therapy showed a 66% greater chance of surviving bladder cancer.
A chemist's research creates tools to make complex drugs more efficiently, with potential breakthroughs in anti-cancer treatments. His work has led to licenses for pharmaceutical companies to study promising drug candidates.
A renowned chemist has synthesized epothilone, a compound derived from bacteria, promising to replace taxol in treating cancer. His successful 25-step synthesis has garnered interest from pharmaceutical companies, paving the way for potential clinical trials and widespread use.
Dr. Rawal has developed a rapid and straightforward reaction that can assemble pieces of complex molecules with high accuracy. This innovation is expected to improve the performance of anticancer drugs like vincristine, which has been used successfully in treating childhood leukemia.
A new combination cancer-killing drug regimen has shown promising results in extending patient survival, with 16% tumor shrinkage and 35% stable disease progression after six months. The orally administered treatment has been well-tolerated and offers a more convenient option for patients compared to traditional IV chemotherapy.
A study found that delaying chemotherapy until disease progression was equivalent to immediate treatment in overall survival and specific survival rates. Patients aged over 70 had a higher chance of not requiring chemotherapy after 10 years.
Researchers found that a paclitaxel combination improved median and long-term survival rates for patients with early-stage SCLC. The treatment also reduced side effects compared to standard chemotherapy.
A new gene expression profile test could identify which breast cancer patients are likely to respond to chemotherapy, helping reduce unproductive treatment and toxicity. The test uses biopsy samples from primary tumors before treatment and measures the tumor's response to docetaxel.
Combining herbal supplements with regular medication without consulting a doctor can lead to adverse interactions. Patients should discuss their herbal supplement use with their primary physician to ensure safe treatment and prevent unexpected complications.
A Canadian-led study found that about 83% of colon cancer patients benefit from traditional chemotherapy, while nearly 17% do not. Further research is needed to provide alternative treatments for those who don't respond to standard therapy.
Researchers have developed novel compounds that significantly improve anti-cancer therapy outcomes. The AvastinTM clinical trial shows that bevacizumab, an anti-angiogenesis agent, can slow or stop tumor growth and increase patient survival when combined with chemotherapy.
A Phase III trial found that pemetrexed and cisplatin significantly improved one-year survival rates for mesothelioma patients to 56.5%, compared to 41.9% for those receiving only cisplatin.
CYC202 demonstrates significant cancer cell death, with 54% of patients testing positive for apoptosis following single agent treatment. Seven patients experienced long-lasting tumour stabilisation in Phase I trials, showcasing potential for selective treatment based on genetic profiles.
A national study found that 43% of patients reported nausea on the day of treatment, and 73% experienced nausea one or more days later. Delayed nausea is a significant problem, affecting twice as many patients who felt ill in the following days compared to those who felt queasy initially.
A randomized clinical trial of over 500 women with primary breast cancer found no significant improvement in disease-free survival or overall survival with high-dose chemotherapy and stem cell transplantation. However, time to recurrence was longer for patients who received the treatment.
A recent study found that high-dose chemotherapy followed by autologous stem cell transplant did not significantly increase survival rates for women with early stage breast cancer. The study, which included 511 patients, showed a higher number of relapses in the treatment group but also nine deaths due to transplantation complications....
Women treated with radiation therapy and chemotherapy had a 61% lower risk of developing breast cancer compared to those who received only radiation. The authors suggest that ovarian hormones play a role in promoting tumor growth after radiation, which may explain the increased breast cancer risk in young women exposed to radiation.
A phase 2 clinical trial found that bortezomib responded positively in 193 relapsed patients, including seven with undetectable myeloma protein and 12 with detectable protein only with immunofixation. The results confirmed significant clinical benefits from therapy.
Researchers found that patients with a negative pretransplantation scan had a favorable outcome, with 25 still in complete remission after a median follow-up of 1,510 days. In contrast, patients with a positive scan relapsed more frequently, highlighting the potential for [F]FDG-PET to identify nonresponders.
Researchers at St. Jude Children's Hospital have successfully treated four pediatric patients with retinoblastoma using a combination of chemotherapy, radiation therapy, and stem-cell transplantation. The study shows promising results, with two out of four patients surviving for over six years without disease recurrence.
A study by Te Velde found that the Pringle manoeuvre increases tumour growth and recurrence after liver surgery, reducing patient survival chances. Medicines preventing blood vessel regeneration can be combined with chemotherapy to control tumours.
Contrast-enhanced MRI is a reliable method to measure blood flow to tumors, allowing for accurate assessment of chemotherapy response and tumor viability. The study found that patients who responded to treatment had significant decreases in angiogenesis, while non-responders showed increases.
A study by Dr. Pio and colleagues found that FLT-PET imaging outperforms FDG-PET in predicting tumor response to chemotherapy in breast cancer patients. The researchers compared the two imaging modalities in 11 newly diagnosed patients, taking scans before treatment began, after the first dose, and following the final cycle.
Pregnant women should undergo thorough breast examinations to detect breast cancer, as diagnosis is often delayed due to hormonal changes. Ultrasonography is the best method for detecting cancerous lumps during pregnancy.
Chemoembolization is the treatment of choice for widespread or diffuse tumors, enabling patients with primary liver cancer to live longer and maintain a quality of life. The procedure uses oil droplets to transport chemotherapy agents directly to the tumor, reducing toxicity and improving outcomes.
A study of 800 women with relapsing ovarian cancer found that combination chemotherapy showed a modest survival benefit compared to platinum-based chemotherapy alone. Women assigned combination therapy survived for an average of five months more than those given platinum therapy.
Susan Bane's research focuses on understanding how anticancer drugs like Taxol interact with tubulin at the molecular level. The study of these interactions could pave the way for the development of more effective next-generation cancer drugs, potentially with improved administration and reduced resistance.